Gladius Capital Management LP Makes New Investment in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Gladius Capital Management LP purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the third quarter, Holdings Channel.com reports. The firm purchased 4,390 shares of the company’s stock, valued at approximately $37,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of AMRX. Victory Capital Management Inc. lifted its position in shares of Amneal Pharmaceuticals by 58.7% during the 3rd quarter. Victory Capital Management Inc. now owns 99,215 shares of the company’s stock valued at $825,000 after acquiring an additional 36,700 shares during the period. Aigen Investment Management LP bought a new stake in Amneal Pharmaceuticals in the third quarter valued at $213,000. Versor Investments LP increased its stake in Amneal Pharmaceuticals by 191.3% in the third quarter. Versor Investments LP now owns 40,200 shares of the company’s stock valued at $334,000 after purchasing an additional 26,400 shares in the last quarter. Chartwell Investment Partners LLC raised its holdings in shares of Amneal Pharmaceuticals by 21.3% during the third quarter. Chartwell Investment Partners LLC now owns 82,410 shares of the company’s stock valued at $686,000 after purchasing an additional 14,477 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of Amneal Pharmaceuticals by 114.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,204,994 shares of the company’s stock worth $10,026,000 after purchasing an additional 642,065 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Stock Down 5.9 %

Shares of NASDAQ:AMRX opened at $8.47 on Friday. The business’s 50 day moving average is $8.58 and its 200 day moving average is $7.66. Amneal Pharmaceuticals, Inc. has a 12-month low of $4.16 and a 12-month high of $9.48.

Wall Street Analysts Forecast Growth

AMRX has been the subject of a number of research analyst reports. Barclays boosted their target price on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Truist Financial boosted their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. StockNews.com upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 11th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a research report on Friday, September 6th. Finally, Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.